Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer
16438
post-template-default,single,single-post,postid-16438,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

Home > Blogs  > Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

19 Mar Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

Posted at 11:53h in Blogs by

Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death, 0.76; 95% CI, 0.63 to 0.93; P=0.008).

Front line therapy with the combo improved median overall survival by 1 year compared to letrozole alone.
(Ref: Hortobagyi et al.NEJM March 10, 2022.)

https://www.linkedin.com/feed/update/urn:li:activity:6910855914283540480

No Comments

Sorry, the comment form is closed at this time.